University of California

Other

Scripps Clinic and Research Foundation

Vical Incorporated

Smith + Nephew

The Scripps Research Institute

Wisconsin Alumni Research Foundation

Cephalon, Inc.

Smith & Nephew Orthopaedics Ag

Naxcor, Inc.

Institute for Medical Research

Gary H. Rhodes

Jon A. Wolff

Philip L. Felgner

Robert W. Malone

Dennis A Carson

Howard B Cottam

Lorenzo M Leoni

Jon Asher Wolff

Philip L Felgner

Eyal Raz

Robert Wallace Malone

Gary H Rhodes

Carlos J Carrera

Tsutomu Nobori

Lei Shi

Aleksa Jovanovic

Wolfgang J Wrasidlo

Salvatore Albani

Christina C N Wu

Kenji Takabayashi

Richard Allen Houghten

Michael L Chan

Gary Rhodes

Tomoko Hayashi

Mary Patricia Corr

John H Vaughan

Mario Chojkier

Mark Roman

Soichi Adachi

Souchi Adachi

Lynn Deng

Eval Raz

Sylvie Barchéchath

Chae-Seo Rhee

Malini Sen

Christina Wu

Maripat Corr

Gregory A Daniels

Benjamin D Sullivan

Sadik C Esener

Rajaram Krishnan

William H Gerwick

Richard S Smith

Michael J Heller

Catriona Jamieson

Richard Syd Kornbluth

Karl Willert

Kelly A Frazer

Gerard J McGarrity

Berent J Prakken

Tadeusz F Molinski

Christian L Barrett

Alberto Martini

Martin Lotz

Hitoshi Kohsaka

Dwayne Stupack

Takashi Suyama

Guangyi Jin

Mathias Schmid

Antonio Catanzaro

Desheng Lu

Hsien C Shih

Robert W Malone

Sherman Fong

Pojen P Chen

Thomasz Haertle

John E Geltosky

Bruce Zuraw

D Bruce Wasson

Meredith L Howell

Jon A Wolff

Michael Heller

Disclosed is a dissolvable, gel-forming film, and methods for its use, comprising a water-soluble cellulose ether, a hydrophilic rheological modifying agent, and an active proteolytic enzyme or other drug substance. The gel-forming film has a water content of less than 15% w/w and is capable of forming a hydrogel when contacted with water or other aqueous medium. The disclosed films achieve delivery of stable proteolytic enzymes to the desired site of action in a manner that provides uniform delivery of the enzymes.

Dissolvable gel-forming film for delivery of active agents

Disclosed is a hydrogel comprising a hydrophilic gelling agent that includes a nonionic cellulose ether, and active thermolysin, wherein the proteolytic activity of the thermolysin does not decrease by more than 20% when stored at room temperature for 6 months.

Stable thermolysin hydrogel

A method to detect ovarian cancer is provided that employs probes and/or primers to detect certain RNA isoform transcripts, as well as kits therefor.

Early ovarian cancer detection diagnostic test based on mRNA isoforms

The present invention is directed to antibodies and fragments thereof having binding specificity for FZD7, which preferably do not substantially interact with (bind to) other FZD family members, and methods of making said anti-FZD7 antibodies and binding fragments thereof. Another embodiment relates to antibodies and binding fragments comprising sequences of VH, VL and/or CDR polypeptides described herein. The invention also contemplates conjugates of anti-FZD7 antibodies and binding fragments. The invention further contemplates use of anti-FZD7 antibodies and binding fragments for tissue engineering. This invention also relates to a transgenic mouse expressing the epitope of anti-FZD7 antibodies and binding fragments thereof. Embodiments also pertain to use of anti-FZD7 antibodies and binding fragments (as well as the identified FZD7 epitope) for diagnosis, assessment, prevention and/or treatment of diseases and disorders associated with aberrant FZD7 expression, such as cancer. The invention further provides peptides for use in anticancer vaccines and for producing antibodies.

FZD7 specific antibodies and vaccines to treat cancer and control stem cell function

Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds.

Wound debridement compositions containing seaprose and methods of wound treatment using same

Provided herein, inter alia, are methods and compositions for modulating TLR-4.

Compositions and methods for modulating TLR4

The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore.

TLR agonists

The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.

Conjugates of synthetic TLR agonists and uses therefor

The invention provides novel compositions&#x2014;lipopeptides and analogs, including somocystinamide A, and somocystinamide A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these lipopeptides and analogs are used to induce apoptosis in a cell, which can be a normal cell, a dysfunctional cell and/or a cancer (tumor) cell. In alternative embodiments, the compositions of the invention, including the lipopeptides and analogs of the invention, and the pharmaceutical compositions comprising them, are used to treat or ameliorate (including slowing the progression of) normal, dysfunctional (e.g., abnormally proliferating) and/or tumor associated blood vessels, including endothelial and/or capillary cell growth; including neovasculature related to (within, providing a blood supply to) a tumor.

Methods for treating or ameliorating a melanoma and killing melanoma cells

Devices and techniques are described that involve a combination of multidimensional electrokinetic, dielectrophoretic, electrophoretic and fluidic forces and effects for separating cells, nanovesicles, nanoparticulates and biomarkers (DNA, RNA, antibodies, proteins) in high conductance (ionic) strength biological samples and buffers. In disclosed embodiments, a combination of continuous and/or pulsed dielectrophoretic (DEP) forces, continuous and/or pulsed field DC electrophoretic forces, microelectrophoresis and controlled fluidics are utilized with arrays of electrodes. In particular, the use of chambered DEP devices and of a properly scaled relatively larger electrode array devices that combines fluid, electrophoretic and DEP forces enables both larger and/or clinically relevant volumes of blood, serum, plasma or other samples to be more directly, rapidly and efficiently analyzed. The invention enables the creation of 'seamless' sample-to-answer diagnostic systems and devices. The devices and techniques described can also carry out the assisted self-assembly of molecules, polymers, nanocomponents and mesoscale entities into three dimensional higher order structures.

Ex-vivo multi-dimensional system for the separation and isolation of cells, vesicles, nanoparticles, and biomarkers

The present invention provides purine analog compounds, as well as compositions and methods of using them, for example, to prevent or treat various diseases and disorders in human and non-human animals. For example, the invention provides for a compound having formula II: 

Purine analogs

Growing community of inventors

Del Mar, CA, United States of America

Dennis A Carson